Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

New Assay Rapidly Identifies Lethal Pathogen Responsible for Clostridium difficile Infection

Published: Tuesday, October 02, 2012
Last Updated: Tuesday, October 02, 2012
Bookmark and Share
BD MAX™ Cdiff test launches in Europe, expanding HAI portfolio on BD MAX™ system.

BD Diagnostics, a segment of BD (Becton, Dickinson and Company), announced that it obtained CE Marking of the BD MAX™ Cdiff Assay. The assay detects the toxin B gene (tcdB), which has been shown to be present in all toxigenic C. difficile and is essential for disease.

Run on the fully automated BD MAX™ System, the assay is designed to rapidly and accurately identify patients with Clostridium difficile infection (CDI), including those caused by hypervirulent strains. Rapidly and accurately identifying these patients enables appropriate treatment and infection control measures to be implemented quickly, which may improve patient outcomes.

“As CDI rates continue to increase in healthcare facilities worldwide, rapid molecular testing for detection of toxigenic C. difficile can help expedite appropriate treatment, reduce length of stay, and improve patient outcomes,” said Tom Polen, President, BD Diagnostics – Diagnostic Systems.  “The BD MAX Cdiff Assay launch is another important milestone in our effort to deliver a range of clinical tests on the BD MAX System, offering laboratories improved efficiency, turnaround time, and productivity.”

According to a recent study in the American Journal of Infection Control, nucleic acid amplification tests provide better sensitivity over enzyme immunoassay and glutamate dehydrogenase testing algorithms for detection of toxigenic C. difficile.  C. difficile is a gram-positive bacterium that is responsible for the development of antibiotic-associated diarrhea and colitis that can progress to toxic megacolon, sepsis and death.  More than 95 percent of antibiotic-associated pseudomembranous colitis cases are caused by CDIs, resulting in more than $1 billion in healthcare costs annually.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

BD Diagnostics MRSA Assay Receives FDA Clearance
Company receives FDA clearance to market the BD MAX™ MRSA XT Assay for use on the fully-automated BD MAX™ System.
Tuesday, January 14, 2014
BD Diagnostics Receive FDA Clearance for StaphSR Assay
BD has received FDA clearance to market the BD MAX™ StaphSR Assay for use on the fully-automated BD MAX™ System.
Tuesday, December 03, 2013
BD announces award to NHS Supply Chain Framework Agreement
New award to the national framework agreement for Microbiology generates interest.
Monday, December 10, 2012
Nationwide Educational Tour Kicks Off on the Future of Molecular Diagnostics
BD Diagnostics convenes experts to address pressing topics for clinical laboratory professionals. Focus will be on the growing role of molecular diagnostics in women’s health, as well as advances in its implementation in the clinical laboratory.
Monday, March 05, 2012
BD Diagnostics Expands Portfolio with Automated Instrumentation Technologies
Company announced the expansion of its microbiology portfolio to include new automated instrumentation technologies that will enable the Company to offer innovative total lab automation solutions to hospitals and laboratories worldwide.
Thursday, February 16, 2012
Scientific News
Grant Supports Project To Develop Simple Test To Screen For Cervical Cancer
UCLA Engineering announces funding from Bill and Melinda Gates Foundation.
Loss Of Y Chromosome Increases Risk Of Alzheimer’s
Men with blood cells that do not carry the Y chromosome are at greater risk of being diagnosed with Alzheimer’s disease. This is in addition to an increased risk of death from other causes, including many cancers. These new findings by researchers at Uppsala University could lead to a simple test to identify those at risk of developing Alzheimer’s disease.
Making Virus Sensors Cheap and Simple
Researchers at The University of Texas at Austin demonstrated the ability to detect single viruses in a solution containing murine cytomegalovirus (MCMV).
Heart Defect Prediction Technology Could Lead to Earlier, More Informed Treatment
Experimental method uses genetics-guided biomechanics, patient-specific stem cells.
Biosensor Detects Molecules Linked to Cancer, Alzheimer's and Parkinson's
Novel biosensor has been proven capable of detecting molecules associated with neurodegenerative diseases and some types of cancer.
Big Data Can Save Lives
The sharing of genetic information from millions of cancer patients around the world could be key to revolutionising cancer prevention and care, according to a leading cancer expert from Queen's University Belfast.
Fast, Simple Test for Colitis
A minimally invasive screening for ulcerative colitis using emerging infrared technology could be a rapid and cost-effective method for detecting disease that eliminates the need for biopsies and intrusive testing of the human body.
Scans Reveal Babies of Mothers with Gestational Diabetes Have More Body Fat
Researchers at Imperial College London have found that the babies born to mothers with gestational diabetes have more body fat at two months of age compared to babies born to healthy mothers.
New Device Could Improve Cancer Detection
UBC researchers develop a microfluidic device to capture circulating tumor cells.
Plasma Biomarkers for Breast Cancer Diagnosis
Plasma lipidomics profiling identified lipid biomarkers in distinguishing early-stage breast cancer from benign lesions.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!